Pet testing still has pricing power
- IDEXX is mainly a companion animal diagnostics company, with CAG making up about 92% of Q1 2026 revenue.
- The core engine is recurring testing revenue from consumables, reference labs, and software used by vet clinics.
- Q1 2026 was strong: CAG Diagnostics recurring revenue grew 11.0% organically.
- Management raised 2026 CAG Diagnostics recurring revenue guidance to 8.7% to 10.7% organic growth.
- The main pressure point is weaker U.S. clinic traffic, with management now planning for a 1.5% decline in 2026.
Strong tests, softer visits
IDEXX has a strong setup because vet clinics keep using its tests once its machines and software are inside the practice. That makes a large part of sales repeatable. In Q1 2026, CAG Diagnostics recurring revenue grew 11.0% organically, and VetLab consumables grew 15.4% organically.
The inVue Dx launch is the fresh growth driver. IDEXX placed 1,100 inVue Dx analyzers in Q1 and still expects 5,500 placements for the full year. Those machines matter because each placement can lead to future sales of single-use consumables.
The bear case is not about whether pets need care. It is about whether owners can afford more tests when money is tight. Management improved its U.S. clinic visit assumption to a 1.5% decline for 2026, but that is still a drag. If visits fall more than planned, the new guidance gets harder.
The stock also needs continued proof. Q1 instrument revenue rose 28.0% organically, helped by the inVue Dx launch. That creates a hard comparison later in 2026 as IDEXX moves past the first launch surge.
Machines seed repeat tests
IDEXX works like a razor and blades business. The company places diagnostic machines in vet clinics. Then it sells the single-use tests, service, lab work, and software that clinics use again and again.
This model can be sticky. A clinic that uses IDEXX instruments, reference labs, and practice software has to change workflows to switch. That helps retention and gives IDEXX room to raise prices when the value is clear.
The model can break if clinics run fewer tests per visit, delay new instrument purchases, or shift to a cheaper rival. It can also slow if a new platform like inVue Dx gets placed, but consumable use per machine takes longer than expected to build.
Tests at the clinic and the lab
Point-of-care veterinary diagnostics
This includes Catalyst, ProCyte, inVue Dx, rapid assays, and related consumables. The instruments seed future test use inside the clinic.
VetLab consumables
These are the single-use test materials used on IDEXX machines. In Q1 2026, VetLab consumables grew 15.4% organically.
Reference laboratory services
IDEXX runs labs that handle tests a clinic does not run in-house. This expands the company beyond the exam room.
Veterinary software and imaging
Products like ezyVet and Neo help clinics run records, billing, and workflows. Software also helps tie the clinic more closely to the IDEXX system.
Water testing
This business sells products that test water for microbes such as coliform and E. coli. Q1 2026 Water revenue grew 7.1% organically.
Livestock, Poultry and Dairy diagnostics
This segment sells tests used for herd, flock, and milk safety. Q1 2026 LPD revenue grew 7.2% organically.
OPTI Medical and other
This is a small human medical diagnostics and out-licensing bucket. It is too small to drive the main thesis.
Mostly companion animal care
Segment mix is based on Q1 2026 revenue from the March 31, 2026 Form 10-Q. CAG is the clear concentration, so this is mostly a bet on pet diagnostics and vet clinic demand.
What could go wrong
Clinic visits keep falling
High impact · Medium oddsIDEXX can grow even when visits slip, but there is a limit. Management plans for U.S. clinic visits to decline 1.5% in 2026. A deeper drop would pressure test volumes and make the raised guidance harder to hit.
inVue Dx placements slow
Medium impact · Medium oddsThe inVue Dx launch is a key growth catalyst. IDEXX placed 1,100 units in Q1 2026 and targets 5,500 for the year. Q1 was not far above a straight-line pace, so the quarterly cadence matters.
Consumable pull-through disappoints
Medium impact · Medium oddsPlacing machines is only the first step. The better business comes when clinics use the machines often and buy more consumables. The FNA use case for inVue Dx is expected to broaden later in 2026, but the speed of revenue lift is still an open question.
Instrument growth faces tough comparisons
Medium impact · High oddsCAG instrument revenue grew 28.0% organically in Q1 2026, helped by inVue Dx. That is a strong number, but it raises the bar for the rest of the year. Management has already noted that instrument revenue could decline as the company laps the early launch surge.
Global costs and currency move against it
Medium impact · Medium oddsIDEXX sells around the world and buys through global supply chains. Currency moves, tariffs, shipping delays, or higher input costs can hurt reported growth or margins. The Q1 filing also notes supply chain and global conflict risks.
In one breath
How does IDEXX make most of its money?
Most revenue comes from the Companion Animal Group. The key stream is recurring diagnostics revenue, such as VetLab consumables, reference lab services, and related clinic services.
Why is inVue Dx important for IDEXX?
inVue Dx is a newer point-of-care analyzer for cytology and blood cell testing. Each placement can add future consumable sales, which is why the 5,500 placement target for 2026 matters.
What is the biggest risk for IDXX stock?
The biggest business risk is that pet owners pull back on vet visits and testing. The stock also needs IDEXX to keep proving that growth can stay strong while clinic visits are still down.